Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ... the FDA listed the final remaining dose of Novo’s semaglutide ...

Eli Lilly spooked ... it's 45% more than Lilly got in Q4 2023, and that fully 40% of its Q4 money haul, $5.4 billion, will come from sales of its GLP-1 weight-loss drugs Mounjaro and Zepbound.

Recent financial results show significant revenue and profit growth, driven by drugs like Zepbound and Mounjaro ... the final quarter of the 2024 fiscal year. Fundamentally speaking, Eli Lilly ...

In a press release this morning, Eli ... more than Lilly got in Q4 2023, and that fully 40% of its Q4 money haul, $5.4 billion, will come from sales of its GLP-1 weight-loss drugs Mounjaro and ...

For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1. ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly ... things went well too. Mounjaro had a very strong ...

Mounjaro is one brand name for the drug tirzepatide from the pharmaceutical manufacturer Eli Lilly. It’s also FDA ... Time for the final verdict: Is Mounjaro better than Ozempic?

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiveness overseer NICE.

Eli Lilly will spend ... device assembly, and packaging for medicines across multiple therapeutic areas," according to a company statement. Sales of both Mounjaro and Zepbound have been held ...